Amerikanische Gesellschaft für Hirudotherapie

Management of complications and compromised free flaps following major head and neck surgery

Retrospective cohort published in Eur Arch Otorhinolaryngol (2015)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportKlinische StudienSicherheit & InfektionskontrolleKucur C et al. · European archives of oto-rhino-laryngology, 2015

Abstract

Microvascular free flaps are preferred for most major head and neck reconstruction surgeries because of better functional outcomes, improved esthetics, and generally higher success rates. Numerous studies have investigated measures to prevent flap loss, but few have evaluated the optimal treatment for free flap complications. This study aimed to determine the complication rate after free flap reconstructions and discusses our management strategies. Medical records of 260 consecutive patients who underwent free flap reconstructions for head and neck defects between July 2006 and June 2010 were retrospectively reviewed for patient and surgical characteristics and postoperative complications. The results revealed that microvascular free flaps were extremely reliable, with a 3.5 % incidence of flap failure. There were 78 surgical site complications. The most common complication was neck wound infection, followed by dehiscence, vascular congestion, abscess, flap necrosis, hematoma, osteoradionecrosis, and brisk bleeding. Twenty patients with poor wound healing received hyperbaric oxygen therapy, which was ineffective in three patients who eventually experienced complete flap loss. Eleven patients with vascular congestion underwent medicinal leech therapy, which was effective. Among the 78 patients with complications, 44 required repeat surgery, which was performed for postoperative brisk bleeding in three. Eventually, ten patients experienced partial flap loss and nine experienced complete flap loss, with the latter requiring subsequent pectoralis major flap reconstruction. Microvascular free flap reconstruction represents an essential and reliable technique for head and neck defects and allows surgeons to perform radical resection with satisfactory functional results and acceptable complication rates.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsFemaleFree Tissue FlapsHead and Neck NeoplasmsHematomaHumansHyperbaric OxygenationMaleMiddle AgedNeck DissectionOhioOsteoradionecrosisPostoperative Complications

Zusammenfassung

260-patient retrospective at Ohio State 2006-2010: 3.5% flap failure rate; 11 patients with vascular congestion received medicinal leech therapy with effective resolution.

Warum dies für die Hirudotherapie relevant ist

This study retrospectively reviewed medical records of 260 consecutive patients who underwent free flap reconstruction for head and neck defects between July 2006 and June 2010, reporting a 3.5% incidence of flap failure and 78 surgical site complications. The abstract states that, among management strategies, eleven patients with vascular congestion were treated with medicinal leech therapy, which was effective. For ASH's domain, this provides a clinical report of leech therapy used for vascular congestion in compromised head and neck free flaps. However, no details are given regarding leech species, protocol, duration, complications, or comparative effectiveness, and leech therapy is a secondary element within a broader surgical-complication management study.

Zitation

Management of complications and compromised free flaps following major head and neck surgery.

Kucur C et al. · European archives of oto-rhino-laryngology, 2015

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.